Sudo Biosciences

United States - Menlo Park, California

• 21/12/2023
• Series B
• $116,000,000

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Related People

Scott ByrdFounder

United States - Zionsville, Indiana

Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.

Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.

LinkedIn https://www.linkedin.com/in/scott-byrd-63b9097/